全球脫髮症市場：按藥物類別和地區分析和預測（2025-2035 年）

Alopecia Areata Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

出版日期: 2025年05月14日 | 出版商:

BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

脫髮症是一種自體免疫疾病，人體的免疫系統錯誤地攻擊毛囊，導致頭髮突然脫落，通常呈現小圓形斑塊。

它會對各個年齡層的男性和女性產生影響，並可能造成嚴重的心理和社會後果。由於人們認知的提高、醫學研究的進步以及新治療方法的出現，全球脫髮症治療市場顯著成長。目前受到關注的治療方法之一是JAK抑制劑。其中一個例子是利曲替尼（商品名 Litfulo），該藥物已被 FDA核准用於治療青少年脫髮症。此項核准對於先前治療選擇有限的患者而言，標誌著向前邁出的重要一步。

脫髮症市場的主要成長要素之一是斑禿脫髮症的不斷上升。脫髮症影響著全球約 2% 的人口，其盛行率正在穩步上升。壓力、空氣污染和生活方式的改變等環境因素導致了這種成長。此外，自體免疫疾病的整體發生率呈上升趨勢，這也是越來越多的人罹患脫髮症的原因。例如，根據美國皮膚病學會的數據，估計光在美國就有大約680萬人患有某種形式的脫髮症。

皮質類固醇和局部免疫療法等傳統治療方法已取得一些成功，但JAK 抑制劑等新型療法正在徹底改變市場，這種療法可以阻斷自體免疫攻擊毛囊的途徑。迄今為止最常用的治療方法包括皮質類固醇和局部免疫療法，這些療法具有一定的有效性，但JAK 抑制劑等較新的治療方法現已出現並正在徹底改變市場。 JAK 抑制劑透過阻斷針對毛囊的自體免疫反應途徑發揮作用。其中一種突破性的治療方法是 Dupixent（dupilumab），這是一種用於治療中度至重度異位性皮膚炎的單株抗體，但它在治療脫髮症患者方面也顯示出良好的效果。 2023年，利曲替尼核准用於治療青少年脫髮症，這成為這些標靶治療的進步如何為患者帶來新希望的典範。

本報告調查了全球脫髮症市場，並總結了主要趨勢、影響市場的因素分析、法律制度、技術和專利趨勢、案例研究、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, leading to sudden hair loss, typically in small patches. It can affect both men and women of all ages, with a significant psychological and social impact. The global market for alopecia areata treatments has experienced substantial growth due to increasing awareness, advancements in medical research, and the introduction of novel therapeutic options. One of the notable examples of current treatments is JAK inhibitors like Ritlecitinib (brand name Litfulo), which received approval by the U.S. FDA for the treatment of alopecia areata in adolescents. This approval marked a significant advancement, given the earlier limited treatment options available for those suffering from this condition.

One of the key drivers of the alopecia areata market is increasing prevalence of alopecia areata. Alopecia areata affects around 2% of the global population, and its prevalence has been steadily increasing. Environmental factors like stress, pollution, and lifestyle changes are contributing to this rise. The increasing incidence of autoimmune disorders overall also means more individuals are prone to developing alopecia areata. For instance, data from the American Academy of Dermatology estimates that approximately 6.8 million people in the U.S. alone have been affected by some form of alopecia.

Moreover, traditional treatments like corticosteroids and topical immunotherapy have been somewhat effective, but the market is now being transformed by novel therapies such as JAK inhibitors, which block the pathways involved in the autoimmune attack on hair follicles. One such breakthrough is Dupixent (dupilumab), a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, which has also shown promise for patients with alopecia areata. The approval of Ritlecitinib for alopecia in adolescents in 2023 is another example of how targeted therapies are creating new hope for those affected by the condition.

Despite the market's growth, there are several challenges that hinder the wider adoption and accessibility of treatments. Advanced treatments such as biologics (e.g., Ritlecitinib and Dupixent) are often expensive, with some costing thousands of dollars per treatment cycle. This high cost of treatment limits access for many patients, particularly in developing regions where healthcare budgets are constrained. The cost barrier is significant in countries outside the U.S. and Europe, where access to biologics is more limited. The high cost of Dupixent, for example, is a point of concern for patients seeking affordable care.

Moreover, not all patients respond the same way to therapies. While JAK inhibitors have shown great promise for some individuals with alopecia areata, they may not work equally well for everyone. The variability in patient responses has led to the need for personalized treatment plans, which complicates the management of the condition and may increase healthcare costs.

In addition, many regions, particularly in Africa, Asia, and Latin America, have limited access to newer treatments due to logistical, financial, and infrastructural barriers. Although global healthcare access is improving, the availability of cutting-edge treatments like JAK inhibitors remains a challenge in these underserved markets.

Market Segmentation:

Segmentation 1: by Drug Class

Corticosteroids
JAK (Janus Kinase) Inhibitors
Others

Segmentation 2: by Region

North America
Europe
Asia-Pacific

The alopecia areata market is experiencing several key emerging trends. One notable trend is the rise of personalized medicine, where treatment plans are tailored to an individual's genetic profile, disease progression, and response to therapy. Biotech companies are increasingly investing in genetic research and biomarkers to identify which patients will benefit most from specific treatments. Another trend is the growing demand for non-invasive therapies, such as topical corticosteroids, minoxidil solutions, and low-level laser therapies. These options are becoming more popular due to their reduced side effects and ease of use, offering more affordable and accessible solutions, especially in regions with limited access to biologics. As healthcare access expands globally, biologic therapies like JAK inhibitors are also gaining traction in emerging markets, with pharmaceutical companies working to improve accessibility through patient assistance programs and distribution partnerships.

In conclusion, the Alopecia Areata (AA) market is positioned for continued growth, driven by advancements in biologic therapies, rising awareness, and increased healthcare access worldwide. Although challenges such as high treatment costs and variability in treatment response remain, the emergence of new therapies, personalized medicine, and the global expansion of access to effective treatments are poised to enhance the management of alopecia areata. The market is also benefiting from the growing emphasis on mental health and the psychological impact of hair loss, leading to more patient-centered care. As innovation continues, both large pharmaceutical companies and smaller biotech firms will drive competition and improve the quality of life for individuals living with alopecia areata.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Markets: Industry Outlook

1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Clinical Trial Analysis
1.5 Epidemiology Analysis
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Challenges
- 1.6.4 Market Opportunities

2. Global Alopecia Areata Market, by Drug Class, ($Million), 2023-2035

2.1 Corticosteroids
2.2 JAK (Janus Kinase) Inhibitors
2.3 Others

3. Global Alopecia Areata Market, by Region, ($Million), 2023-2035

3.1 North America
- 3.1.1 Key Findings
- 3.1.2 Market Dynamics
- 3.1.3 Market Sizing and Forecast
  - 3.1.3.1 North America Alopecia Areata Market, by Country
    - 3.1.3.1.1 U.S.
3.2 Europe
- 3.2.1 Key Findings
- 3.2.2 Market Dynamics
- 3.2.3 Market Sizing and Forecast
  - 3.2.3.1 Europe Alopecia Areata Market, by Country
    - 3.2.3.1.1 Germany
    - 3.2.3.1.2 U.K.
    - 3.2.3.1.3 France
    - 3.2.3.1.4 Italy
    - 3.2.3.1.5 Spain
3.3 Asia Pacific
- 3.3.1 Key Findings
- 3.3.2 Market Dynamics
- 3.3.3 Market Sizing and Forecast
  - 3.3.3.1 Asia Pacific Alopecia Areata Market, by Country
    - 3.3.3.1.1 Japan

4. Global Alopecia Areata Market: Competitive Landscape and Company Profiles

4.1 Key Developments and Strategies
- 4.1.1 Mergers and Acquisitions
- 4.1.2 Synergistic Activities
- 4.1.3 Business Expansions and Funding
- 4.1.4 Product Launches and Approvals
- 4.1.5 Other Activities
4.2 Company Profiles
- 4.2.1 Eli Lilly and Company
  - 4.2.1.1 Overview
  - 4.2.1.2 Top Products / Product Portfolio
  - 4.2.1.3 Target Customers/End-Users
  - 4.2.1.4 Key Personnel
  - 4.2.1.5 Analyst View
- 4.2.2 Pfizer Inc
  - 4.2.2.1 Overview
  - 4.2.2.2 Top Products / Product Portfolio
  - 4.2.2.3 Target Customers/End-Users
  - 4.2.2.4 Key Personnel
  - 4.2.2.5 Analyst View
- 4.2.3 Sun Pharmaceutical Industries Ltd
  - 4.2.3.1 Overview
  - 4.2.3.2 Top Products / Product Portfolio
  - 4.2.3.3 Target Customers/End-Users
  - 4.2.3.4 Key Personnel
  - 4.2.3.5 Analyst View
- 4.2.4 Arcutis Biotherapeutics
  - 4.2.4.1 Overview
  - 4.2.4.2 Top Products / Product Portfolio
  - 4.2.4.3 Target Customers/End-Users
  - 4.2.4.4 Key Personnel
  - 4.2.4.5 Analyst View
- 4.2.5 Bristol-Myers Squibb
  - 4.2.5.1 Overview
  - 4.2.5.2 Top Products / Product Portfolio
  - 4.2.5.3 Target Customers/End-Users
  - 4.2.5.4 Key Personnel
  - 4.2.5.5 Analyst View
- 4.2.6 AbbVie
  - 4.2.6.1 Overview
  - 4.2.6.2 Top Products / Product Portfolio
  - 4.2.6.3 Target Customers/End-Users
  - 4.2.6.4 Key Personnel
  - 4.2.6.5 Analyst View
- 4.2.7 Regeneron Pharmaceuticals
  - 4.2.7.1 Overview
  - 4.2.7.2 Top Products / Product Portfolio
  - 4.2.7.3 Target Customers/End-Users
  - 4.2.7.4 Key Personnel
  - 4.2.7.5 Analyst View
- 4.2.8 Aclaris Therapeutics
  - 4.2.8.1 Overview
  - 4.2.8.2 Top Products / Product Portfolio
  - 4.2.8.3 Target Customers/End-Users
  - 4.2.8.4 Key Personnel
  - 4.2.8.5 Analyst View